Patents by Inventor Alan D. Borthwick
Alan D. Borthwick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5162345Abstract: Compounds are described of the formula: ##STR1## and physiologically acceptable salts thereof, in which R.sub.1 -R.sub.7 are defined hereinafter.The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion concentration and thus may be useful for the treatment of cardiovascular disorders such as hypertension.Type: GrantFiled: August 20, 1990Date of Patent: November 10, 1992Assignee: Glaxo, S.p.A.Inventors: Claudio Semeraro, Dino Micheli, Daniele Pieraccioli, Giovanni Gaviraghi, Alan D. Borthwick
-
Patent number: 5155112Abstract: The present invention provides the compounds of formula (I) ##STR1## and salts and solvates thereof wherein R.sup.1 represents a hydrogen or fluorine atom or a hydroxy group, R.sup.2 represents a fluorine atom or a hydroxyl or C.sub.1-6 alkoxy group and B represents a purine base, and describes processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of viral infections, particularly those caused by the Herpetoviridae.Type: GrantFiled: November 23, 1990Date of Patent: October 13, 1992Assignee: Glaxo Group LimitedInventors: Richard Storer, Ian L. Paternoster, Alan D. Borthwick, Keith Biggadike
-
Patent number: 5100896Abstract: The present invention provides a compound of formula (I) ##STR1## and salts and solvates and pharmaceutically acceptable derivatives thereof, and describes processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of viral diseases, especially those caused by the Herpetoviridae.Type: GrantFiled: July 23, 1990Date of Patent: March 31, 1992Assignee: Glaxo Group LimitedInventors: Alan D. Borthwick, Keith Biggadike, Barrie E. Kirk, Richard Storer, Niall G. Weir, Anthony D. Baxter, Chi L. Mo
-
Patent number: 5091395Abstract: Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group;R.sub.2 and R.sub.3 independently represent a C.sub.1-6 straight or branched alkyl chain or alkoxy group;R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent;R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group.The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion reflux and thus may be useful for the treatment of cardiovascular disorders such as hypertension.Type: GrantFiled: November 4, 1988Date of Patent: February 25, 1992Assignee: Glaxo S.p.A.Inventors: Claudio Semeraro, Dino Micheli, Daniele Pieraccioli, Giovanni Gaviraghi, Alan D. Borthwick
-
Patent number: 5051432Abstract: Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group:R.sub.2 represents a group ##STR2## (where A is a bond or a methylene group and R.sub.7 is phenyl C.sub.1-4 alkyl; or R.sub.2 represents a group CH.sub.2 CH.sub.2 NR.sub.8 R.sub.9 (where R.sub.8 is hydrogen or C.sub.1-4 alkyl and R.sub.9 is C.sub.1-4 alkyl, phenyl C.sub.1-4 alkyl or benzoyl C.sub.1-4 alkyl); or R.sub.2 represents a C.sub.1-4 alkyl group substituted by nitrile.R.sub.3 represents a C.sub.1-6 straight or brached alkyl chain or alkoxy group;R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent;R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group.Type: GrantFiled: September 19, 1990Date of Patent: September 24, 1991Assignee: Glaxo, S.p.A.Inventors: Claudio Semeraro, Dino Micheli, Daniele Pieraccioli, Giovanni Gaviraghi, Alan D. Borthwick
-
Patent number: 4963571Abstract: Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group;R.sub.2 and R.sub.3 independently represent a C.sub.1-6 straight or branched alkyl chain or alkoxy group;R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent;R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group.R.sub.7 represents a C.sub.1-4 alkyl group [optionally substituted by hydroxy, C.sub.1-3 alkoxy or trifluoromethyl or by a group NR.sub.8 R.sub.9 where NR.sub.8 R.sub.9 forms a saturated 5 to 7 membered ring optionally containing an additional heleroatom which is oxygen]; or R.sub.7 represents a phenylC.sub.1-2 alkyl group in which the portion is optionally substituted by 1 to 3 C.sub.1-3 alkyl or C.sub.1-3 alkoxy groups or halogen atoms.Type: GrantFiled: November 16, 1988Date of Patent: October 16, 1990Assignee: Glaxo S.p.A.Inventors: Claudio Semeraro, Dino Micheli, Daniele Pieraccioli, Giovanni Gaviraghi, Alan D. Borthwick
-
Patent number: 4946851Abstract: Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkylgroup;R.sub.2 and R.sub.3 independently represent a C.sub.1-6 straight orbranched alkyl chain or alkoxy group;R.sub.4 represents a C.sub.1-4 alkyl group;R.sub.5 represents a group CH.dbd.CR.sub.6 R.sub.7 where R.sub.6 is a hydrogen atom or C.sub.1-3 alkyl group and R.sub.7 represents an aryl, pyridyl or cyano group; or R.sub.5 represents the group C.tbd.CR.sub.8 where R.sub.8 is an aryl group.The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion influx and thus may be useful for the treatment of cardiovascular disorders such as hypertension.Type: GrantFiled: October 28, 1988Date of Patent: August 7, 1990Assignee: Glaxo, S.p.A.Inventors: Claudio Semeraro, Dino Micheli, Daniele Pieraccioli, Giovanni Gaviraghi, Alan D. Borthwick
-
Patent number: 4935548Abstract: Compounds are described of the formula ##STR1## wherein R.sub.1 represents a formyl or nitrile group or a group OCH.sub.2 A where A represents hydroxy, C.sub.1-4 alkoxy or D(CH.sub.2).sub.n NR.sub.7 R.sub.8 (where R.sub.7 and R.sub.8 independently represent hydrogen or C.sub.1-4 alkyl and n is 2 or 3);R.sub.2 and R.sub.3 independently represent a C.sub.1-6 straight or branched alkyl chain or alkoxy group;R.sub.4 represents a C.sub.1-4 alkyl group;R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent;R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group.The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion influx and thus may be useful for the treatment of cardiovascular disorders such as hypertension.Type: GrantFiled: October 21, 1988Date of Patent: June 19, 1990Assignee: Glaxo S.p.AInventors: Claudio Semeraro, Dino Micheli, Daniele Pieraccioli, Giovanni Gaviraghi, Alan D. Borthwick
-
Patent number: 4880801Abstract: Compounds of the general formula (I) ##STR1## (R is H, alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl or CHO, R.sup.1 and R.sup.2 are independently halogen, alkyl, alkoxy, hydroxyl, cyano, nitro or --NR.sup.3 R.sup.4 where R.sup.3 and R.sup.4 are independently H or alkyl and R.sup.2 may be H) and their salts have selective .alpha..sub.2 -adrenoreceptor antagonist action.The compounds may be prepared by amination of compounds of the general formula (II) ##STR2## (where R.sup.1 and R.sup.2 are as defined above and X is a leaving group.Type: GrantFiled: May 26, 1988Date of Patent: November 14, 1989Assignee: Glaxo Group LimitedInventors: John Kitchin, Peter C. Cherry, Adrian J. Pipe, Andrew J. Crame, Alan D. Borthwick
-
Patent number: 4806533Abstract: Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group;R.sub.2 and R.sub.3 independently represent a C.sub.1-6 straight or branched alkyl chain or alkoxy group;R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent;R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group.R.sub.7 represents a C.sub.1-4 alkyl group [optionally substituted by hydroxy, C.sub.1-3 alkoxy or trifluoromethyl or by a group NR.sub.8 R.sub.9 where NR.sub.8 R.sub.9 forms a saturated 5 to 7 membered ring optionally containing an additional heleroatom which is oxygen]; or R.sub.7 represents a phenylC.sub.1-2 alkyl group in which the phenyl portion is optionally substituted by 1 to 3 C.sub.1-3 alkyl or C.sub.1-3 alkoxy groups or halogen atoms.Type: GrantFiled: February 19, 1987Date of Patent: February 21, 1989Assignee: Glaxo, s.p.a.Inventors: Claudio Semeraro, Dino Micheli, Daniele Pieraccioli, Giovanni Gaviraghi, Alan D. Borthwick
-
Patent number: 4769367Abstract: Compounds of the general formula (I) ##STR1## (wherein R is H, alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl or CHO; and R.sup.1 and R.sup.2 each represents H, fluorine or chlorine);and their salts have selective .alpha..sub.2 -adrenoreceptor antagonist action.The compounds may be prepared by amination of compounds of the general formula (II): ##STR2## (wherein X is a leaving group).Type: GrantFiled: June 25, 1986Date of Patent: September 6, 1988Assignee: Glaxo Group LimitedInventors: Peter C. Cherry, Adrian J. Pipe, John Kitchin, Alan D. Borthwick, Richard J. Coles, Derek Burn
-
Patent number: 4496579Abstract: Compounds are disclosed of general formula ##STR1## where R is H, C.sub.1-6 alkyl optionally substituted by C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl or alkynyl, C.sub.3-7 cycloalkyl, aralkyl or --CHOand the physiologically acceptable salts thereof. The compounds have selective .alpha..sub.2 -adrenoreceptor antagonist action and are indicated as potentially useful for the treatment or prevention of migraine, thrombosis, diabetes, obesity, hypertension, constipation, paralytic ileus, senile dementia and analepsis, and for use in appetite suppression and for the treatment of depression; they may be formulated as pharmaceutical compositions in conventional manner. The compounds may be prepared, for example, by amination of a compound of formula ##STR2## where X is a leaving group such as halogen or a hydrocarbylsulphonyloxy group.Type: GrantFiled: October 25, 1983Date of Patent: January 29, 1985Assignee: Glaxo Group LimitedInventors: Andrew J. Crame, Alan D. Borthwick